LEXINGTON, Mass., Sept. 3, 2015 /PRNewswire/ -- Pulmatrix, Inc., (NASDAQ: PULM) will present at the Rodman & Renshaw 17th Annual Global Investment Conference on Thursday, September 10, 2015 at 11:40 am EDT. As part of the presentation, Robert W. Clarke, Ph.D., Chief Executive Officer for Pulmatrix, will provide an update on the Company's business and its pipeline of inhaled therapeutics.
A live webcast of the presentation may be accessed in the investors section of the Company's website at www.pulmatrix.com. A replay of the presentation will be available on the Company's website for 90 days following the presentation.
About Pulmatrix
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with cystic fibrosis (CF), as well as PUR1500, an inhaled product for the treatment of idiopathic pulmonary fibrosis. In addition, Pulmatrix intends to pursue opportunities in major pulmonary diseases through collaborations, which includes PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease (COPD) in partnership with Mylan N.V. Pulmatrix's product candidates are based on iSPERSE™, its proprietary dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.
|
Investor Contact |
Media Contact |
|
Tom Baker Direct: 617-532-0624 |
David Schull, Russo Partners Direct: (858) 717-2310 |
Logo - http://photos.prnewswire.com/prnh/20150616/223308LOGO
SOURCE Pulmatrix, Inc.
